|
|
|
The new Howard Hughes Medical Institute computing cluster at Janelia Farm puts a premium on expandability and speed. By Randy Barrett July 26, 2010 | Computational biologists have a need for speed. The computing cluster at the Howard Hughes Medical
|
The challenges facing the primary producers of workflow and pipeline software—Accelrys and InforSense—may not be so much with each other as evolving in step with pharma’s needs. By John Russell July 26, 2010 | It’s tempting to paint the commercial workflow
|
Bio IT World Expo Europe 2010(5 7 Oct, Hannover, Germany) – Final Agenda Just Released CONFERENCE TRACKS IT Infrastructure & Informatics Data Storage, Analysis and Visualization – View Agenda NGS Data Management Sequencing Systems, Storage, and Analysis – View Agenda IT Infrastructure &
|
Bio-IT World | Iya Khalil is a fast talker, she readily admits. But she’s not afraid to admit that her company, Gene Network Sciences (GNS), has had to pause and change its tune over the past decade in order to establish fruitful business partnerships with pharma. However, the latest version of its supercomputer-based scientific platform called REFS (Reverse Engineering, Forward Simulation) and efforts to harness complete ‘omic and clinical data are putting GNS on the right track.
|
March 16, 2010 | Iya Khalil is a fast talker, she readily admits. But she’s not afraid to admit that her company, Gene Network Sciences (GNS), has had to pause and change its tune over the past decade in order to establish fruitful business partnerships with pharma (see, “GNS Charts ‘Unknown’ Biology,” Bio•IT World, Oct 2006). However, the latest version of its supercomputer-based scientific platform called REFS (Reverse Engineering, Forward Simulation) and efforts to harness complete ‘omic and clinical data are putting GNS on the right track.
|
Bio-IT World | Imagine administering a small-molecule drug that could effectively, specifically, and permanently silence its protein target. That should be the ideal of any drug-discovery program, but most small-molecule drugs interact with their target in a reversible, transient and depressingly non-specific manner. One solution to the problem would be to focus on a different class of small molecules—compounds that form a strong, covalent bond with their desired target.
|
Bio-IT World | While working at Pfizer 9 years ago, Andrew Hopkins and his colleague Colin Groom coined the phrase “the druggable genome”—a systematic analysis of the number of druggable targets in the human genome. In 2007, Hopkins made the bold decision to quit industry for academia. Now, with patents filed, compounds being synthesized, biophysics and informatics operations up and running, Hopkins granted Bio•IT World this exclusive interview.
|
Bio-IT World | Imagine administering a small-molecule drug that could effectively, specifically, and permanently silence its protein target. That should be the ideal of any drug-discovery program, but most small-molecule drugs interact with their target in a reversible, transient and depressingly non-specific manner. One solution to the problem would be to focus on a different class of small molecules—compounds that form a strong, covalent bond with their desired target.
|
January 20, 2010 | While working at Pfizer in the U.K. some 9 years ago, Andrew Hopkins and his colleague Colin Groom coined the phrase “the druggable genome”—a systematic analysis of the number of druggable targets in the human genome (see, “The Druggable Genome,” Bio•IT World, Oct 2002). In 2007, Hopkins made the bold decision to quit industry for academia. Weighing various offers, he chose to move north of the border, to the ‘City of Discovery’—Dundee, Scotland —where the ship in which Scott sailed to the Antarctic was built. Hopkins says it’s taken a good two years to adapt from industry, basically starting from scratch, but things are finally starting to come together. With patents filed, compounds being synthesized, biophysics and informatics operations up and running, Hopkins granted Bio•IT World this exclusive interview.
|
Bio-IT World Weekly Update: Nov 10
|
Bio-IT World Weekly Update: Nov 3
|
Accelrys’ Success Formula: Strength and Scope - Oct 28th
|
Bio-IT World Weekly Update: Oct 27
|
Bio-IT World Weekly Update: Oct 20
|
- GE forms "GE Healthymagination Fund,"
- RainDance extends capabilities of Sequence Enrichment Solution
- Illumina launches cBot at ASHG
|
- ParaScale and Zmanda offer Disk-to-Cloud (D2C) backup solution
- Broad Institute names board of directors
- National Human Genome Research Institute lists Recovery Act awards
|
Gene Logic's New Trajectory
|
Bio-IT World Weekly Update: Oct 13
|
Bio-IT World Weekly Update Oct 6
|
Bio-IT World Weekly Update Oct 6
|
The Role of Analytics in Transforming Healthcare Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders. Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are: - Potentially stunning return on investment at multiple levels.
- A 500%, or better, increase in application development time by directly executing business requirements
- Improved customer retention
- A 50% possible reduction in training time
Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.
Next-gen Cloud-based eClinical New technologies are available to leverage Cloud Computing in managing clinical trial data. This paper discusses a next generation eClinical
platform that: - Speeds trial set up
- Accommodates changes with zero downtime
- Integrates effectively with other clinical trial technology systems
It is offered with either software-as-a-service (SaaS), or turnkey infrastructure options in which the user organization operates their own cloud using their IT teams, within their data centers. Read this paper to learn and decide how best to leverage cloud computing’s many strengths for your organization’s particular needs.
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
Bio-IT World proudly presents the Bio-IT World Web Symposia Series covering a broad array of topics within the life sciences and drug development enterprise.
Leveraging BPM to Increase Efficiencies in Clinical Trial Case Management
August 3, 2010 | 1:00 – 2:30 p.m. EST
Sponsored by: Pegasystems
Program Details | Register Here
|
|
|